沙库巴曲缬沙坦治疗老年左室射血分数降低心力衰竭的效果

Abstract
Figure/Table
References (25)
Related Citation (15)

Download: PDF (577 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the effect of Sakubatrevalsartan in the treatment of heart failure in the elderly with left ventricular ejection fraction (LVEF) reduction. Methods 89 elderly patients with heart failure were selected from Liuzhou People′s Hospital from June 2017 to December 2018, they were divided into control group (n = 44) and study group (n = 45) by random number table method. Control group was treated with routine Western medicine, and study group was treated with Sakubatrevalsartan on the basis of control group. Clinical efficacy, cardiac function, renal function and adverse reactions were compared between two groups. Results After treatment, total effective rate of study group was significantly higher than that of control group (P < 0.05). The walking distance of 6 minutes after treatment in two groups was longer than that before treatment, left ventricular end diastolic dimension was shorter than that before treatment, LVEF was higher than that before treatment, heart rate was slower than that before treatment, and the improvement in study group was significantly better than that in control group (P < 0.05). After treatment, blood urea nitrogen and serum creatinine of two groups were lower than before treatment, estimated glomerular filtration rate was higher than before treatment, and the improvement of study group was significantly better than that of control group (P < 0.05). There was no significant difference in the incidence of adverse reactions between two groups (P > 0.05). Conclusion Sakubatrevalsartan can effectively improve the cardiac and renal function of elderly patients with heart failure due to the reduction of LVEF, with definite curative effect and good safety, and has certain clinical application value.

Key words： Heart failure Sakubatrevalsartan Left ventricular ejection fraction reduction Elderly

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	QI Jie ZHUO Liu′an WU Feixue WEI Wenwen

Cite this article:

QI Jie ZHUO Liu′an WU Feixue WEI Wenwen. Effect of Sakubatrevalsartan in the treatment of heart failure in the elderly with left ventricular ejection fraction reduction[J]. 中国医药导报, 2020, 17(8): 68-71.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I8/68

[1] 高飞，易世娟，许晓洁.五苓散治疗慢性心力衰竭的系统评价[J].国际中医中药杂志，2018，40（12）：1160-1164.
[2] 王欣玲，许嘉鸿.慢性心力衰竭患者的医院-社区联合双向管理模式研究[J].国际心血管病杂志，2017，44（3）：189-191.
[3] Zhou X，Tao Y，Chen Y，et al. Serum chemerin as a novel prognostic indicator in chronic heart failure[J]. J Am Heart Assoc，2019，8（15）：e012091.
[4] 单瑞，杨培根.老年慢性心衰患者血清胆汁酸水平与炎症因子及心室重构的关系[J].天津医药，2018，46（1）：42-45.
[5] 谢诚，叶静，缪丽燕，等.61例心力衰竭患者血管紧张素受体脑啡肽酶抑制剂沙库巴曲缬沙坦的应用分析[J].中国药房，2019，30（8）：1124-1127.
[6] 黄崚.急性心力衰竭诊断和治疗指南[J].疑难病杂志，2010，9（7）：557.
[7] 张长东，肖书娜，尚小珂，等.肺动脉高压患者压力-容积关系分析与纽约心脏病协会心功能分级的相关性[J].中国介入心脏病学杂志，2017，25（9）：512-519.
[8] 李平，李佑美.曲美他嗪联合美托洛尔治疗冠心病心力衰竭对血浆BNP影响及疗效观察[J].海南医学院学报，2016，22（2）：126-128.
[9] 付文科，孙玉发，郝卫军，等.左西孟旦治疗老年缺血性心肌病所致急性失代偿性心力衰竭的疗效和安全性分析[J].中华老年心脑血管病杂志，2017，19（2）：153-155.
[10] 徐琪，王洪旗，辛国勇.多病因对老年心力衰竭患者临床特征的影响分析[J].河北医学，2018，24（9）：1512-1515.
[11] 曹秋梅.老年心力衰竭的特点与优化治疗[J].中国医刊，2012，47（5）：9-12.
[12] Kjeldsen SE，Narkiewicz K，Burnier M，et al. The PARAGON heart failure trial-ongoing investigation of the angiotensin receptor antagonist/neprilysin inhibitor sacubitril/valsartan in heart failure patients with hypertension and preserved ejection fraction [J]. Blood Press，2019，28（4）：215-216.
[13] 王欣丽，陈亮，姜紫凡，等.MTHFR C677T基因多态性与老年心力衰竭患者心室重构的相关性[J].临床荟萃，2017，32（3）：212-215，219.
[14] 边圆，王甲莉，程凯，等.2016年欧洲心脏病学会急性心力衰竭指南解读[J].中华急诊医学杂志，2016，25（7）：849-853.
[15] 陈莉，逯伟达，吴媛媛，等.沙库巴曲缬沙坦对射血分数降低的心力衰竭Ⅳ级患者生化指标和左心室结构的干预作用[J].中华老年医学杂志，2019，38（5）：525-528.
[16] Bonaventura A，Wohlford GF，Vecchié A，et al. In hospital initiation of sacubitril/valsartan：a new PARADIGM for acute decompensated heart failure? [J]. J Cardiovasc Pharmacol，2019，74（1）：1-3.
[17] 李江，曹佳宁，文娴，等.沙库巴曲缬沙坦治疗老年人扩张型心肌病致慢性心力衰竭的疗效观察[J].中华老年医学杂志，2019，38（5）：520-524.
[18] 余意君，刘涛，邹武松，等.体外反搏改善缺血性心力衰竭患者疗效及无创心功能检测指标[J].重庆医学，2017，46（31）：4360-4363，4366.
[19] 回亚男.超声心动图评价心力衰竭模型大鼠心功能及其与血清B型钠尿肽的关系[J].中国老年学杂志，2017， 37（23）：5799-5800.
[20] 高小群，廉哲勋，齐玉军，等.肾功能损伤对N末端B型利钠肽原应用于心力衰竭诊断的影响[J].中国循环杂志，2016，31（12）：1189-1193.
[21] 徐磊，裴东，詹鹏，等.ICU急性失代偿性心力衰竭患者肾功能恶化与患者死亡的相关性研究[J].中国急救医学，2017，37（8）：699-704.
[22] 牛潇玉，赵晓燕.沙库巴曲缬沙坦及培哚普利治疗慢性心力衰竭的疗效对比[J].重庆医学，2019，48（11）：1874-1877.
[23] Aimo A，Emdin M，Maisel AS. Sacubitril/valsartan，cardiac fibrosis，and remodeling in heart failure[J]. J Am Coll Cardiol，2019，73（23）：3038-3039.
[24] 陈升强.沙库巴曲缬沙坦钠联合卡维地洛对慢性心力衰竭的疗效研究[J].中国医药科学，2019，9（22）：69-71，105.
[25] 董小伟，王红雷，来利红，等.沙库巴曲缬沙坦联合比索洛尔治疗慢性心力衰竭的临床研究[J].现代药物与临床，2018，33（11）：2791-2794.